Valthos
The Business Development role at Valthos focuses on expanding business opportunities within the US Government, particularly for biodefense programs at the Department of War (DoW). Responsibilities include developing a comprehensive strategy for government acquisitions, conducting outreach, managing proposal development, and facilitating negotiations. The role requires collaboration with technical teams to align product offerings with mission needs and the ability to navigate governance structures and funding processes. An ideal candidate will have a background in federal contracting and a relevant network in the biodefense community.
Valthos is an applied biological intelligence company focused on developing and deploying innovative software and AI technologies to outsmart biological evolution, aiming to enhance biodefense and safeguard humanity. The company specializes in real-time identification of biological threats and the design of medical countermeasures, harnessing frontier AI systems to address challenges in biosecurity and health. Committed to building a diverse and skilled team, Valthos is backed by prominent investors including OpenAI and is actively hiring exceptional talent from leading organizations in technology and health.
AI Biodefense Startup Valthos Launches With $30 Million, OpenAI Backing
Oct 25, 2025
OpenAI-Backed Valthos Raises $30 Million to Combat AI-Enabled Biological Threats
Oct 24, 2025
Biodefense Startup Valthos Emerges From Stealth With $30M Funding From OpenAI, Thiel’s Founders Fund
Oct 27, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Valthos.
Valthos didn’t post a salary, so this is our estimate from similar listings.
OpenAI Backs a New Venture Trying to Thwart AI Bio-Attacks
Oct 24, 2025